Cargando…

Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy

BACKGROUND: To analyze and compare the economic outcomes of adjuvant chemotherapy with capecitabine plus oxaliplatin (referred to as the XELOX strategy) and of S-1 (the S-1 strategy) for gastric cancer patients after D2 gastrectomy. METHODS: A Markov model was developed to simulate the lifetime dise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Bin, Li, Te, Cai, Jian, Xu, Yuejuan, Zhao, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301844/ https://www.ncbi.nlm.nih.gov/pubmed/25526802 http://dx.doi.org/10.1186/1471-2407-14-984

Ejemplares similares

Adjuvant Chemotherapy for Elderly Patients with Gastric Cancer after D2 Gastrectomy
por: Jin, Ying, et al.
Publicado: (2013)

Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer
por: Serrano, Mariana, et al.
Publicado: (2022)

Effect of laparoscopic gastrectomy on compliance with adjuvant chemotherapy in patients with gastric cancer
por: Bao, Huizheng, et al.
Publicado: (2017)

Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy
por: Cho, Jang Ho, et al.
Publicado: (2017)

Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients
por: Yu, Shan, et al.
Publicado: (2020)

Why a D2 gastrectomy plus adjuvant chemotherapy is insufficient in locally advanced gastric cancer
por: Sebastián Solé, Z, et al.
Publicado: (2016)

A new scoring system to evaluate adjuvant chemotherapy for patients with T2N0M0 gastric cancer after D2 gastrectomy
por: Xu, Quan, et al.
Publicado: (2022)

Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study
por: Chen, Lei, et al.
Publicado: (2021)

Adjuvant chemotherapy may be unnecessary for ypT0-2N0 gastric cancer patients after neoadjuvant chemotherapy and curative gastrectomy
por: Shao, Xinxin, et al.
Publicado: (2023)

Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study
por: Ren, Deng-Feng, et al.
Publicado: (2018)

Time-related improvement of survival in resectable gastric cancer: the role of Japanese-style gastrectomy with D2 lymphadenectomy and adjuvant chemotherapy
por: Grau, Juan J, et al.
Publicado: (2006)

Adjuvant Chemotherapy Improves Survival in Stage III Gastric Cancer after D2 Surgery
por: Chang, Shin-Chun, et al.
Publicado: (2018)

The prognostic value of lymph node ratio for local advanced gastric cancer patients with adjuvant chemoradiotherapy after D2 gastrectomy
por: Hu, Min, et al.
Publicado: (2018)

Clinical impact of postoperative interval until adjuvant chemotherapy following curative gastrectomy for advanced gastric cancer
por: Takashima, Yusuke, et al.
Publicado: (2021)

ADJUVANT CHEMORADIOTHERAPY AFTER SUBTOTAL OR TOTAL GASTRECTOMY AND D2 LIMPHADENECTOMY INCREASES SURVIVAL IN ADVANCED GASTRIC CANCER?
por: ANDREOLLO, Nelson Adami, et al.
Publicado: (2019)

Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer
por: Li, Zi-Yu, et al.
Publicado: (2011)

Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1
por: Hisashige, Akinori, et al.
Publicado: (2013)

Laparoscopic Gastrectomy for Gastric Cancer with Peritoneal Dissemination after Induction Chemotherapy
por: Tsutsumi, Satoshi, et al.
Publicado: (2013)

Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T(3-4a)N0M0 Gastric Cancer Patients after D2 Gastrectomy
por: Chen, Shi, et al.
Publicado: (2017)

Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System
por: Bai, Yongrui, et al.
Publicado: (2017)

Prognostic significance of mucinous component in gastric adenocarcinoma after radical D2 gastrectomy
por: Cai, Lei, et al.
Publicado: (2018)

The Safety and Feasibility of Laparoscopic Gastrectomy after Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
por: Ge, Rui, et al.
Publicado: (2022)

Laparoscopic gastrectomy for elderly gastric-cancer patients: comparisons with laparoscopic gastrectomy in non-elderly patients and open gastrectomy in the elderly
por: Li, Zheng-Yan, et al.
Publicado: (2020)

Palliative gastrectomy plus chemotherapy versus chemotherapy alone for incurable advanced gastric cancer: a meta-analysis
por: Wu, Pei, et al.
Publicado: (2018)

Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study
por: Fuse, Nozomu, et al.
Publicado: (2016)

Delayed Presentation of Gastric Volvulus with Gastric Outlet Obstruction after Laparoscopic Sleeve Gastrectomy
por: Batayyah, Esam, et al.
Publicado: (2022)

Association of Adjuvant Chemotherapy With Overall Survival Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
por: Lin, Jian-Xian, et al.
Publicado: (2022)

Prognostic Model of D2 Radical Gastrectomy Combined with Neoadjuvant Chemotherapy for Gastric Cancer
por: Wang, Guangjun, et al.
Publicado: (2023)

Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study
por: Liang, Yanrui, et al.
Publicado: (2021)

Intussusception after reconstruction following gastrectomy for gastric cancer
por: Xia, Feng, et al.
Publicado: (2021)

Local recurrence of gastric cancer after total gastrectomy: an unusual presentation
por: Martella, Bruno, et al.
Publicado: (2012)

A Prognostic Nomogram and Heat Map to Predict Survival in Stage II/III Gastric Cancer Patients After Curative Gastrectomy Followed by Adjuvant Chemotherapy
por: Shi, Litong, et al.
Publicado: (2022)

Competing risk nomogram predicting initial loco-regional recurrence in gastric cancer patients after D2 gastrectomy
por: Wang, Shu-Bei, et al.
Publicado: (2019)

Correction to: Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study
por: Liang, Yanrui, et al.
Publicado: (2021)

Association Among Blood Transfusion, Postoperative Infectious Complications, and Cancer-Specific Survival in Patients with Stage II/III Gastric Cancer After Radical Gastrectomy: Emphasizing Benefit from Adjuvant Chemotherapy
por: Xiao, Hua, et al.
Publicado: (2020)

The Efficacy of Taxanes- and Oxaliplatin-Based Chemotherapy in the Treatment of Gastric Cancer After D2 Gastrectomy for Different Lauren Types
por: Zheng, Zhen, et al.
Publicado: (2016)

Prognostic effect of excessive chemotherapy cycles for stage II and III gastric cancer patients after D2 + gastrectomy
por: Li, Yi-Fan, et al.
Publicado: (2023)

Updated Adjuvant Chemotherapy for Gastric Cancer
por: Takayama, Toshizo, et al.
Publicado: (2023)

Efficacy of S-1 or Capecitabine Plus Oxaliplatin Adjuvant Chemotherapy for Stage II or III Gastric Cancer after Curative Gastrectomy: A Systematic Review and Meta-Analysis
por: Jeong, Sang-Ho, et al.
Publicado: (2022)

A Novel Inflammatory-Nutritional Prognostic Scoring System for Stage III Gastric Cancer Patients With Radical Gastrectomy Followed by Adjuvant Chemotherapy
por: Wang, Nan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cdc5fsjg6r6au5m7a93a34gu7g